Abstract: A method and system to digitally measure area/volume and body surface area of a person and estimate corresponding density and composition as related to a fixed reference frame. This Digital Image Volume Assessment System (DIVAS™) has many desirable features, such as computerized accuracy, precision, convenience, minimal operator expertise and subject compliance is required, and it is economical and expeditious.

Abstract: A method of determining and monitoring the safety of a foodstuff by subjecting the foodstuff to bioelectrical impedance analysis including measurement and calculation of values of resistance, reactance, impedance, capacitance, and phase angle of the foodstuff, and then tracking the values over time to illustrate freshness, palatability and safety of the foodstuff, and ascertaining difference in rate of change from established averages of freshness and palatability to show possible contamination of the foodstuff.

Abstract: A process of determining if a foodstuff is fresh or has previously been frozen. The foodstuff is subjected to bioelectrical impedance analysis including measurement or calculation of values of resistance, reactance, impedance, capacitance, and/or phase angle. The results illustrate whether or not the foodstuff has been previously frozen or is fresh. Also provided is a process of selecting a preparation method, a packaging and shipping method, or disposition of a foodstuff. First determining a palatability value for the foodstuff. Second determining as a function of the determined palatability value whether or not the foodstuff is to be prepared for consumption, is to be packaged and shipped, or is to be disposed of.

Abstract: A method of organ and tissue vitality assessment for surgery, including subjecting the organ or tissue to bioelectrical impedance analysis; taking initial and serial measurements of resistance, reactance, capacitance, phase angle, impedance or any value derived therefrom; and tracking the initial and serial measurements to establish vitality, healing, and condition of the organ or tissue for surgery.

Abstract: A method and system to determine freshness and palatability (tenderness, juiciness, and flavor) of live foodstuffs (meat, fish, fowl, fruit and vegetables) including the steps of; utilizing bioelectrical impedance analysis in a biological subject model for measurement and composition analysis; and a system of using the results of the utilizing step procedure to illustrate an objective scale of palatability; a ‘Palatability Index’. Also a method of whole body and regional organ and tissue vitality assessment in a biological entity, human, animal, fruit or vegetable, including the steps of: utilizing bioelectric impedance analysis in a biological model for composition analysis; and using the results of the utilizing step to provide an objective assessment of volume and distribution of fluid and tissues, and electrical health of cells and membranes of the organ or tissue.

Abstract: A method for determining illness of a biological entity, progression to non-acute death of the biological entity, and/or timing of non-acute death of the biological entity. A comparison of measured values of resistance, reactance, phase angle, extracellular and intracellular water volumes, and membrane status of whole body and regions of the entity show hallmarks of the state of health of the entity.

Abstract: A method for detecting the presence and severity of illness, the effectiveness of treatment interventions, and the ability to change treatment to be more effective or aggressive, to optimize outcomes, to limit morbidity and mortality, and to illustrate a patient's prognosis, including the steps of using whole body impedance analysis to measure a patient's resistance, reactance, phase angle, and related electrical values at a healthy baseline, and thereafter in relation to the patient's complaints, evaluating temporal or progressive nature of negative values or diminution of the measured values of resistance, reactance, phase angle, and related electrical values over time.

Abstract: A method and system for use in treating a patient receiving an anticoagulant or a substance containing warfarin to optimize therapy and prevent an adverse drug response. This system employs surrogate markers or indicators including blood levels of the anticoagulant to determine the next required dose for a patient. Since the surrogate markers are employed as a percent change in status, virtually any indicator can be used. Surrogate markers could include any measure of the effectiveness of the anticoagulant's action. Given the effectiveness of the anticoagulant's action relative to the surrogate markers, a change in anticoagulant dose is calculated by the system. Conversely, by employing this system, one could determine the expected result of the anticoagulant dose change on the surrogate markers.

Abstract: A method and apparatus for use in detecting the presence and severity of illness, the effectiveness of treatment interventions, and the ability to change treatment to be more effective or aggressive, to optimize outcome, limit morbidity and mortality and illustrate the patent's prognosis. A method for determining illness of a biological entity, progression to non-acute death of the biological entity, and/or timing of non-acute death of the biological entity, and a method of organ vitality assessment for transplantation of the organ being assessed.

Abstract: A method for determining illness, progression to death, and timing of death of a biological entity, in which whole body measurements of electrical impedance and composition of the biological entity are taken and recorded at predetermined intervals of time for providing initially measured values and serially measured values, and then the initially measured values are compared to normal values and to the serially measured values to determine hallmarks or characteristics of illness, progression to death and timing to death of the biological entity.

Abstract: A method, system and apparatus for use in treating a patient receiving a biological substance, such as a cancer vaccine, to optimize therapy and prevent an adverse response. This system employs surrogate markers or indicators including blood levels of the vaccine to determine the next required dose for a patient. Since the surrogate markers may be employed as a percent change in status, virtually any indicator can be used. Surrogate markers could include any measure of the effectiveness of the vaccine's action. Given the effectiveness of the vaccine's action relative to the surrogate markers, a change in vaccine dose is calculated by the system. Conversely, by employing this system, one could determine the expected result of the vaccine dose change on the surrogate markers.

Abstract: A method, apparatus and system for use in treating a patient receiving an antineoplastic drug to optimize therapy and prevent an adverse drug response. This system employs surrogate markers or indicators including blood levels of the antineoplastic drug to determine the next required dose for a patient. Since the surrogate markers are employed as a percent change in status, virtually any indicator can be used. Surrogate markers could include any measure of the effectiveness of the antineoplastic drug's action. Given the effectiveness of the antineoplastic drug's action relative to the surrogate markers, a change in antineoplastic drug dose is calculated by the system. Conversely, by employing this system, one could determine the expected result of the antineoplastic drug dose change on the surrogate markers.

Abstract: A method and system for utilization of bioelectrical impedance analysis (BIA) in a biological model for body composition analysis (BCA) to provide an objective assessment of an organ's and/or biological entity's volume and distribution of fluids and tissue as well as the electrical health of cells and membranes. A method for determining illness of a biological entity, progression to death of the biological entity, and/or timing of death of the biological entity, and a method of organ vitality assessment for transplantation of the organ being assessed.

Abstract: A method, system and apparatus for use in treating a patient receiving a biological substance, such as a cancer vaccine, to optimize therapy and prevent an adverse response. This system employs surrogate markers or indicators including blood levels of the vaccine to determine the next required dose for a patient. Since the surrogate markers may be employed as a percent change in status, virtually any indicator can be used. Surrogate markers could include any measure of the effectiveness of the vaccine's action. Given the effectiveness of the vaccine's action relative to the surrogate markers, a change in vaccine dose is calculated by the system. Conversely, by employing this system, one could determine the expected result of the vaccine dose change on the surrogate markers.